Instrument Inactif

Communiqués AVEO Pharmaceuticals, Inc.

Actions

AVEO

US0535883070

Produits pharmaceutiques

Communiqués

19/01/23	AVEO PHARMACEUTICALS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
19/01/23	LG Chem Completes Acquisition of AVEO Oncology	GL
18/01/23	AVEO Pharmaceuticals : Merger Agreement - Form 8-K	PU
18/01/23	AVEO PHARMACEUTICALS, INC. : Other Events (form 8-K)	AQ
06/01/23	AVEO Oncology Stockholders Approve Acquisition by LG Chem	GL
05/01/23	AVEO PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
03/01/23	AVEO Oncology Reminds Stockholders to Vote “FOR” All-Cash Transaction with LG Chem in advance of the Special Meeting of Stockholders	AQ
02/12/22	AVEO Pharmaceuticals : Merger Agreement - Form 8-K	PU
02/12/22	AVEO PHARMACEUTICALS, INC. : Other Events (form 8-K)	AQ
07/11/22	AVEO: Q3 Earnings Snapshot	AQ
07/11/22	AVEO PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
07/11/22	AVEO Oncology Reports Third Quarter 2022 Financial Results	AQ
19/10/22	AVEO ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AVEO Oncology - AVEO	BU
18/10/22	AVEO PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
12/10/22	U.S. Patent & Trademark Office Allows AVEO Oncology’s Patent Application Covering Use of FOTIVDA® for the Treatment of Refractory Advanced Renal Cell Carcinoma	AQ
21/09/22	AVEO Oncology Announces Participation at the Cantor Fitzgerald Oncology & HemOnc Conference	AQ
31/08/22	AVEO Oncology Announces Participation at Investor Conferences in September	AQ
09/08/22	AVEO PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
04/08/22	AVEO: Q2 Earnings Snapshot	AQ
04/08/22	AVEO PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
04/08/22	AVEO Pharmaceuticals : Oncology Reports Second Quarter 2022 Financial Results - Form 8-K	PU
04/08/22	AVEO Oncology Reports Second Quarter 2022 Financial Results	AQ
28/07/22	AVEO Oncology to Announce Second Quarter 2022 Financial Results on August 4, 2022	AQ
22/06/22	AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ERBITUX® (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with Recurrent or Metastatic HNSCC	AQ
21/06/22	AVEO Oncology Announces Updated NCCN Clinical Practice Guidelines Elevate FOTIVDA® (tivozanib) to Category 1 Treatment for Relapsed or Refractory Advanced (R/R) Renal Cell Carcinoma (RCC) Patients	AQ